Results obtained during docking, analysis of hydrogen bonds and free energy calculation indicated that JNJ-26854165 is a more suitable agent to BCR-ABL T315I inhibition than the other two candidates. In the present study, our group utilizes computational analysis to investigated interactions and compare the efficiency of designed small molecules to inhibit the BCR-ABL T315I functional domain. Compounds such as PBA2, CD-200 and JNJ-26854165 have been introduced as novel candidates for CML treatment in different in vitro/in vivo studies and show potential inhibitory impacts on BCR-ABL T315I. Some mutations in BCR-ABL protein such as T315I reduces the effectiveness of drugs in patients. It has been shown that BCR-ABL plays a central role in the emergence of CML and targeting this molecule is a part of all the related therapies. Chronic myeloid leukemia (CML), is a cancer that is not exempt to this rule. One of the main problems in this field is drug resistance, which in most cases, incidence of mutations in the target molecules is responsible for not responding to prescribed treatments. Despite considerable advances made in cancer research, the treatment of this disease is still facing numerous challenges. Today, a significant proportion of health costs is dedicated to cancer diagnosis and treatment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |